Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Receivables (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Receivables over the past 3 years, most recently at $9.8 million for Q4 2025.

  • Quarterly results put Receivables at $9.8 million for Q4 2025, up 110.44% from a year ago — trailing twelve months through Dec 2025 was $9.8 million (up 110.44% YoY), and the annual figure for FY2025 was $9.8 million, up 110.44%.
  • Receivables for Q4 2025 was $9.8 million at Tonix Pharmaceuticals Holding, up from $5.1 million in the prior quarter.
  • Over the last five years, Receivables for TNXP hit a ceiling of $9.8 million in Q4 2025 and a floor of $2.3 million in Q3 2023.
  • Median Receivables over the past 3 years was $4.6 million (2024), compared with a mean of $5.5 million.
  • Peak annual rise in Receivables hit 165.0% in 2024, while the deepest fall reached 49.5% in 2024.
  • Tonix Pharmaceuticals Holding's Receivables stood at $9.2 million in 2023, then crashed by 49.5% to $4.6 million in 2024, then skyrocketed by 110.44% to $9.8 million in 2025.
  • The last three reported values for Receivables were $9.8 million (Q4 2025), $5.1 million (Q3 2025), and $4.3 million (Q2 2025) per Business Quant data.